Eiger BioPharmaceuticals, Inc. (EIGRQ) vs Matinas Biopharma Holdings, Inc. (MTNB)

Eiger BioPharmaceuticals, Inc. and Matinas Biopharma Holdings, Inc. are both Biotechnology companies. Eiger BioPharmaceuticals, Inc. and Matinas Biopharma Holdings, Inc. are of similar size ($2.6M and $2.4M). Matinas Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 2,139.4% against 17.0%. Matinas Biopharma Holdings, Inc. has the higher net margin (0.00% vs −475.3%) and the higher return on invested capital (−419.3% vs −3,674.6%). Across the 16 metrics below, Matinas Biopharma Holdings, Inc. leads on 10 and Eiger BioPharmaceuticals, Inc. on 6.

Valuation

Metric EIGRQ MTNB Biotechnology median
P/E n/m n/m 7.88
P/S 0.80 0.24 11.47
P/B n/m 0.57 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 4.37 0.05 10.73
Earnings yield (601.00%) (731.25%) (28.84%)
Free cash flow yield (594.47%) (595.22%) (23.03%)

Profitability

Metric EIGRQ MTNB Biotechnology median
Gross margin 99.85% 0.00% 65.16%
Operating margin (455.12%) 0.00% 0.00%
Net margin (475.26%) 0.00% 0.00%
Free cash flow margin (474.11%) 0.00% 0.00%
Return on equity (367.00%) (154.28%) (57.72%)
Return on assets (94.31%) (98.53%) (49.22%)
Return on invested capital (3,674.55%) (419.27%) 0.00%

Growth

Metric EIGRQ MTNB Biotechnology median
Revenue growth (TTM) 16.98% 2,139.41% 5.64%
EPS growth (last fiscal year) 27.11% 59.84% —
Revenue growth, 5-year CAGR — 55.69% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EIGRQ MTNB Biotechnology median
Debt to equity (2.84) 0.00 0.00
Current ratio 0.71 0.85 4.73
Net debt to EBITDA (0.22) 0.62 0.96

Dividend

Metric EIGRQ MTNB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric EIGRQ MTNB Biotechnology median
Market cap 2.55m 2.41m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack